We knew Sasha before she lost everything, and we wanted to give her her future back.
In the quiet arithmetic of a single misplaced letter among three billion, a nine-year-old girl named Sasha Lipworth lost her voice, her movement, and the simple joy of blowing out birthday candles. Her parents, refusing to accept the silence that rare disease so often demands, have assembled scientists across two continents to engineer a treatment that has never existed — a molecular patch designed for one child, one mutation, one life. The race unfolding in Australian and American laboratories is not only a story of parental love outrunning institutional medicine, but a glimpse at what personalized genetic therapy might one day mean for the many thousands of children whose conditions are too rare to attract the world's attention.
- A single corrupted letter in Sasha's DNA has stolen five years of her childhood — her speech, her motor skills, her ability to signal pain — leaving her in the grip of hundreds of seizures every day.
- With no pharmaceutical company willing to develop a drug for a patient population of one, her parents abandoned their careers and built a research team from scratch, funding the science themselves.
- Scientists at Queensland University of Technology have grown miniature brains from Sasha's own cells and already corrected her genetic splicing error in the lab — three candidate RNA therapies are showing real promise.
- The path from laboratory success to a child's first dose now hinges on nearly a million dollars in funding and a regulatory timeline tight enough that every week of delay narrows the window when her still-developing brain might respond.
- If the treatment works, the principles behind it could serve as a replicable model for the fifteen to thirty percent of all genetic diseases driven by the same class of RNA splicing errors — making one girl's cure the foundation of a new medical frontier.
Nadine and David Lipworth carry videos on their phones of a daughter who no longer exists in quite the same way — a little girl on a scooter, a little girl singing before four birthday candles. Within months of those recordings, something in Sasha's genetic code began dismantling everything she had learned. By four and a half, she could no longer speak, hold a spoon, or play. Hundreds of seizures arrived each day. She is nine now, and has been nonverbal longer than she ever had words.
In early 2024, researchers at the University of Sydney traced the cause to a spontaneous mutation in Sasha's SLC6A1 gene — a single letter altered in three billion. Only one other person on earth carries the same variant. The mutation doesn't change the protein's blueprint so much as it corrupts the editing process, like a film cut in the wrong place, so that the protein responsible for calming the brain's electrical storms is never properly assembled.
Finding no institutional path forward, the Lipworths built one themselves. They recruited scientists from Australia and the United States to develop antisense oligonucleotides — synthetic RNA strands engineered to bind precisely to the site of Sasha's splicing error and mask it, redirecting the cellular machinery toward the correct cut. At Queensland University of Technology, researcher Dr. Laura Croft has spent months nurturing three-dimensional brain organoids grown from Sasha's own reprogrammed blood cells. Three candidate therapies have already corrected the error in that lab-grown tissue. One is showing particular promise at restoring the protein her brain needs.
The science is moving. The money is not keeping pace. Identifying the best candidate will cost $75,000; toxicology testing and manufacturing a clinical-grade drug will require nearly a million dollars more. The Lipworths are racing not just against funding gaps but against biology itself — the window in which Sasha's still-developing brain might relearn what it has lost is not infinite. If everything aligns, she could receive her first dose around her tenth birthday in March.
What they are constructing, however, reaches beyond one child. An estimated fifteen to thirty percent of all genetic diseases involve the same class of RNA splicing errors that broke Sasha's code. A successful treatment here would not simply be a miracle for one family — it would be a proof of concept, a replicable method, a reason to believe that personalized genetic medicine could one day be as unremarkable as a surgical referral. That future is still being built, piece by piece, in laboratories and fundraising campaigns, while a nine-year-old girl waits and her parents refuse to stop running.
Nadine and David Lipworth keep family videos on their phones. In one, their daughter Sasha zooms past on an aquamarine scooter, beaming. In another, she sings Happy Birthday before blowing out four candles. She was four years old then. Within months, something invisible in her genetic code began to unravel everything she had learned to do.
By age four and a half, Sasha had lost the ability to speak, to hold a spoon, to use a toilet, to play with toys. She was having hundreds of seizures each day. Now nine, she has been nonverbal longer than she was ever able to speak. For five birthdays in a row, she couldn't blow out a single candle. She requires round-the-clock care. Her parents, who quit their jobs to tend to her full-time, have devoted themselves to a single mission: finding a way to give her back what the disease took.
In March 2024, researchers at the University of Sydney identified the culprit—a spontaneous mutation in Sasha's SLC6A1 gene, a single letter changed among the three billion base pairs in her DNA. Only one other person in the world is known to carry this exact variant. The mutation doesn't alter the protein code itself. It alters how that code gets edited together, like a television broadcast where the scissors cut in the wrong place, severing the crucial plot twist and rendering everything that follows incomprehensible. The protein that should calm the brain's electrical signals never gets made correctly. The result is seizures, the progressive loss of skills, a child locked inside a body that no longer obeys her.
With no institutional funding, the Lipworths assembled a team of scientists from Australia and the United States to develop something that has never existed before: a treatment designed specifically for Sasha. They are building antisense oligonucleotides—synthetic strands of RNA engineered with such precision that they can bind to the exact spot where Sasha's genetic scissors go wrong, masking that spot like tape over a wound. In a laboratory at Queensland University of Technology, Dr. Laura Croft has been growing miniature brains from Sasha's own blood cells, reprogrammed into stem cells. For 140 days, she has tended these three-dimensional brain organoids, feeding them nutrient-rich media. Three candidate treatments have already corrected the splicing error in Sasha's lab-made brain tissue. One shows promise at restoring the protein function her brain desperately needs.
The science is moving fast. The obstacle is money. Confirming which treatment works best will cost $75,000. Toxicology testing in a U.S. laboratory and manufacturing a clinical-grade drug will cost $900,000 more. The Lipworths are racing against time and against the window when intervention might still work—when Sasha's brain is still developing, still capable of relearning what it has forgotten. If all goes well, if the funding comes through, if the regulatory pathway holds, Sasha could receive her first dose by her tenth birthday in March. Her parents dream of her regaining speech, motor control, the ability to communicate pain or harm. A trial of a similar treatment for another seizure disorder found that children regained lost skills and developed new ones: language, communication, the ability to move.
What the Lipworths are building is not just a treatment for their daughter. It is a blueprint. An estimated fifteen to thirty percent of all genetic diseases are caused by mutations affecting RNA splicing—the same mechanism that broke Sasha's code. If this works, if they succeed in treating a single child with a disease so rare that she represents the entire patient population, the principles they discover could help the next child, and the next, and the next. One day, David imagines, this will be as routine as surgery: you go to the doctor, the doctor finds your mutation, and develops a personalized genetic treatment that targets it. But that future requires infrastructure that doesn't yet exist, and it requires people like the Lipworths to build it while their daughter waits, while the seizures continue, while the clock runs.
Notable Quotes
It's taking too long to get this done.— David Lipworth, Sasha's father
I cannot leave this world until my daughter can tell someone if she is in pain or being harmed.— Nadine Lipworth, Sasha's mother
The Hearth Conversation Another angle on the story
What does it mean that only one other person in the world has Sasha's mutation?
It means she's not just rare—she's singular in a way that makes traditional drug development impossible. There's no patient population to study, no market incentive for a pharmaceutical company. It's just Sasha, and her parents, and a team of scientists who believe she deserves a treatment anyway.
Why did they choose to develop an antisense oligonucleotide instead of some other approach?
Because it's precise. It can target the exact spot where her genetic scissors go wrong. Other approaches might work on other mutations, but this one is tailored to her specific letter change. It's like using a key cut for one lock.
The lab-grown brains—how does that actually help them know if the treatment will work in her real brain?
It's a test run. They can see if the treatment corrects the splicing error, if the protein gets made properly, if the cells behave the way they should. It's not a guarantee, but it's the closest thing to proof before you put it in a living child.
What happens if the treatment doesn't work?
They don't say. But they're moving fast because they know the earlier the intervention, the better the outcome. Every month matters when a child's brain is still developing.
Why are the parents so focused on this being bigger than Sasha?
Because they've seen what precision medicine could do. They know that if they crack this, they've created a pathway for the next child with a different ultra-rare mutation. They're not just fighting for their daughter. They're building something that doesn't exist yet.
What's the hardest part—the science or the money?
The money. The science is almost there. They need a million dollars to finish what they've already figured out how to do.